Investigation on the relationship between hallucination and non-motor symptoms in patients with Parkinson's disease
CHEN Ze-jie,CAO Chen-jie,YU Shu-yang,ZUO Li-jun,HU Yang,WANG Fang,ZHANG Wei
DOI: https://doi.org/10.3969/cma.j.issn.1674-0785.2013.15.010
2013-01-01
Abstract:Objective To investigate the incidence and relationship with other non-motor symptoms of Parkinson's Disease(PD) patients with hallucinations. Methods 105 PD patients with disease duration within ten years were recruited. The patients were divided into hallucination group and non-hallucination group according to the second item of Neuropsychiatric Inventory(NPI). The patients were collected for general information and the use of medicine, and a comparison study was conducted by using PD related non-motor symptoms scales. Results(1)12 cases(11.4%) of PD patients were accompanied by hallucinations;(2)The disease duration in hallucination group, 4.08±2.47 years, was longer than that in non-hallucination group,2.56±2.24 years,with no significance(P= 0.062), and two groups were not different in gender, age and age at onset(P>0.05), Hoehn-Yahr staging and the score of Unified Parkinson Disease Rating Scale(UPDRS) Ⅲ in hallucination group(stage 2.63±1.13, 38.58±18.10) was significantly higher than that in non-hallucination group(stage 1.90±0.69, 25.07±14.32)(P<0.05);(3) The incidences of depression, anxiety, fatigue, sleep disorders, daytime somnolence and RBD were all significantly higher in hallucination group than that in non-hallucination group(91.7% vs. 60.2%, 66.7% vs. 30.1%, 100.0% vs. 66.3%, 100.0% vs. 62.4%, 66.7% vs. 34.4%, 42.8% vs. 10.7%, P<0.05); the scores of Montreal Cognitive Assessment, Hamilton Depression Scale, Hamilton Anxiety Scale, Fatigue Scale-14, Pittsburgh Sleep Quality Index, Epworth Sleeping Scale and the number of autonomic dysfunctions assessed by The Scale for Outcomes in PD for Autonomic Symptoms were all significantly different between hallucination group and non-hallucination group(20.5 vs. 24.0, 23.0 vs. 10.0, 17.5 vs. 7.0, 10.0 vs. 8.0, 10.0 vs. 6.0, 7.5 vs. 4.0, 14.0 vs. 8.0, P<0.05) expect Mini-Mental State Examination and Modified Apathy Estimate Scale(P>0.05), and actual sleep time and sleep efficiency in hallucination group were significantly lower than that in non-hallucination group,(5.96±1.95)hours vs.(6.92±1.39)hours,(76.04±16.04)% vs.(85.52±14.38)%, P<0.05, and the numbers of gastrointestinal dysfunction and cardiovascular dysfunction in hallucination group were more than that in non-hallucination group(P<0.05);(4) There was no difference in levodopa equivalent doses between the two groups(P>0.05);(5) Hoehn-Yahr Staging and the score of Hamilton Depression Scale were the risk factors of PD with hallucinations with the OR value of 2.996 and 1.096, respectively. Conclusion The incidence of hallucination in PD with disease duration within ten years was 11.4%. Hallucination is closely correlated with Hoehn-Yahr Staging and non-motor symptoms, including cognition impairment, mood disorders(depression, anxiety), fatigue, sleep disorder and autonomic dysfunction.